@FierceMedDev: Illumina hits U.K. company with prenatal test patent suit. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: J&J hosts oral biologics startup at its new incubator to help it find Remicade's replacement. More from FierceDrugDelivery | Follow @VarunSaxena2
@EmilyWFierce: FDA warning on power morcellators triggers "broad transformation" in clinical practice. WSJ story (sub. req.) | Follow @EmilyWFierce
> AliveCor will use its algorithm to analyze electrocardiograms (ECGs) from traditional cardiac event monitors for the first time under a new pilot program with Preventice Solutions. It will use the AliveCor analytics program to help improve its internal workflow by prioritizing the most critical ECGs. More
> iRhythm Technologies adds another $10 million to the Series D round that it raised last year, bring the total to $27.3 million to back its cardiac arrhythmia wearable diagnostic device. Filing
> The NIH's National Institute on Alcohol Abuse and Alcoholism (NIAAA) is holding a competition to develop a better wearable alcohol biosensor. Submissions including a working prototype are due by Dec. 1 with winners announced on or after Feb. 15, 2016. The first prize is $200K and the second prize is $100K. Release
> The New York Times questions and evaluates the usefulness of a number of health apps. Story
Biotech News
@FierceBiotech: ICYMI yesterday: Department reorganizations at Biogen Idec raise fears of future cuts. Report | Follow @FierceBiotech
@JohnCFierce: $KITE sees its TCR work as a key distinguishing factor in an increasingly crowded field. Sets up Kite EU in $21M deal. Release | Follow @JohnCFierce
> Esperion's potential PCSK9 spoiler scores more positive data. News
> Galapagos registers another setback as J&J dumps anti-inflammatory pact. Story
> CAR-T player Kite Pharma buys its way into Europe and pads its anticancer arsenal. Article
> GlaxoSmithKline and J&J back a $100M new Alzheimer's R&D project. Report
Pharma News
@FiercePharma: ICYMI yesterday: All clear for Actavis to become Allergan as EU watchdogs approve $66B merger. Article | Follow @FiercePharma
@EricPFierce: DEA says it is not the cause of shortages of scheduled drugs, that it is just misunderstood. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce
> Hep C meds cost-effective, but affordable? With new 46% discounts, maybe. Article
> Endo's shown it's willing to spend. But with Salix gone, what's left worth buying? More
> Imbruvica cocktail stalls CLL in new trial, raising hopes for bigger market. Report
Drug Delivery News
> Efforts at intracochlear drug delivery to treat hearing loss gaining momentum. Item
> Depomed picks up loan for second half of $1.05B Nucynta acquisition from J&J. More
> New optogenetics technique does away with genetic modification. Story
> Glide touts studies of its delivery system as it prepares to take on Novartis' Sandostatin. Item
> J&J hosts oral biologics startup at its new incubator to help it find Remicade's replacement. Article
Pharma Manufacturing News
> Malaysia's CCM Duopharma Biotech adds plants to compete better. More
> Actavis becomes Allergan and looks to manufacturing for cutting costs. Item
> WuXi to bulk up cell therapy manufacturing in Philadelphia. Article
> New York set to get another drug manufacturing project. Story
> Florida CDMO gets taxpayer boost for expansion, 100 jobs. Report
Pharma Asia News
> Astellas says stem cell research promising on kidney failure. Item
> India and U.S. scientists battle over virulence of swine flu strain in India. Report
> Big Three Asia pharma markets poised to soar in 2015, reports say. Story
> South Korea's Green Cross pushes into cell therapy manufacturing in China. More
> Doctor outreach at heart of Daiichi Sankyo $39 million Medicaid lawsuit settlement. Article